Skip Navigation
ArriVent Biopharma logo
  • About
    • Our Company
    • Executive Team
    • Partners
    • Our Culture
  • Programs
    • Pipeline
    • Scientific Presentations
    • Clinical Trials
    • Expanded Access Policy
  • News
    • Press Releases
  • Careers
    • Who We Are
    • Job Opportunities
  • Contact Us
News

Press Releases

  • All
  • 2022
  • 2021
  • 07.05.2022

    ArriVent Biopharma Announces First Patient Enrolled in Global Phase 1b Trial of Furmonertinib in Advanced or Metastatic Non-Small Cell Lung Cancer with EGFR or HER2 Mutations
  • 02.15.2022

    ArriVent Biopharma Appoints Bahija Jallal to its Board of Directors
  • 12.31.2021

    Aarvik Therapeutics and ArriVent Biopharma Announce Research Collaboration to Advance Novel Oncology Drug Candidate Using Aarvik’s Proprietary Modular Antibody Platform
  • 06.30.2021

    ArriVent Biopharma Launches with Up To $150M in Series A Financing and Strategic Licensing Agreement for Clinical-Stage Oncology Asset
ArriVent Biopharma logo
info@arrivent.com

©2023 ArriVent Biopharma. All Rights Reserved.

  • Privacy Policy
  • Terms & Conditions
  • Site Map